On August 5, Eastern Time, pharmaceutical giant Eli Lilly (ticker: LLY) announced that its highly anticipated oral weight-loss drug Orforglipron met primary endpoints in a Phase III clinical trial, with data far exceeding expectations. Following the announcement, Lilly's shares surged more than 8% in premarket trading, lifting the SPDR S&P Biotech ETF (XBI) and the Health Care Select Sector SPDR Fund (XLV) higher. This major breakthrough not only solidifies Lilly's dominance in metabolic diseases but also injects strong bullish sentiment into the US healthcare sector.
Phase III Data Overwhelmingly Strong, Oral Weight Loss Efficacy Comparable to Injectables
According to Lilly's official press release, the global multicenter Phase III trial named ATTAIN-1 enrolled more than 3,000 adult patients with obesity or overweight accompanied by at least one comorbidity. Results showed that after 72 weeks of treatment, patients receiving the highest dose of Orforglipron (50 mg oral daily) achieved an average weight reduction of 17.8%, compared with only 2.1% in the placebo group. On key secondary endpoints, over 40% of treated patients achieved at least 20% weight loss, a level never seen before in oral small-molecule GLP-1 drugs.
Lilly CEO David Ricks said: "The convenience of oral dosing combined with efficacy close to injectables will completely transform the treatment experience for obesity patients. Orforglipron has the potential to become the world's first once-daily oral GLP-1 receptor agonist, offering a new option for patients who cannot or do not want to receive injections." The company plans to submit new drug applications to the US FDA and European EMA simultaneously in the second half of 2026.
Weight-Loss Drug Market Reshaped: Oral Formulations Become a Key Battleground
The global weight-loss drug market is expanding at an astonishing pace. According to the latest Goldman Sachs research report, the global obesity drug market will exceed $150 billion by 2030, with oral formulations expected to account for about 40% of the share. Currently, the only oral GLP-1 drug on the market is Novo Nordisk's Rybelsus (semaglutide tablets), but its bioavailability and weight-loss magnitude have not reached the level Orforglipron has demonstrated. Lilly's data not only gives it a technological high ground in the competition with Novo Nordisk but also sends a strong signal to rivals in tracks such as novel oral PYY/GLP-1 dual receptor agonists.
Wall Street analysts generally believe Orforglipron has the potential to become the next "blockbuster king" within three years of launch. JPMorgan pharmaceutical analyst wrote in a client report: "Oral weight-loss drugs are one of the most anticipated catalysts in global healthcare. Lilly's data almost replicates the weight-loss performance of its blockbuster injectable Tirzepatide (brand name: Zepbound), while the compliance advantage of oral formulations will significantly expand the addressable population. Orforglipron is expected to generate global sales of more than $25 billion by 2030."
Lilly's Earnings Flexibility and Valuation Reset: Market Repricing the Oral Weight-Loss Track
Lilly's current market capitalization has exceeded $850 billion, making it the largest healthcare stock in the US market. Following the Phase III data release, multiple investment banks quickly raised their target prices. Morgan Stanley raised its target price from $1,150 to $1,300, citing "oral weight-loss drugs will significantly smooth the supply bottleneck in GLP-1 capacity expansion and reduce dependence on the cold supply chain for injectables." Citigroup expects Lilly's earnings per share over the next 12 months could increase by an additional $2.50 due to Orforglipron's approval.
Notably, Orforglipron uses a small-molecule chemical structure, unlike the current mainstream peptide-based GLP-1 drugs. It has lower production costs and can be manufactured on a large scale as oral solid dosage forms, which will greatly alleviate the widespread shortages of semaglutide and tirzepatide globally. Lilly's manufacturing facilities in the US, Ireland, and China are already paving the way for oral drug commercialization. The company expects to supply over 5 million patients in the first year after approval.
Healthcare Sector Investment Logic: A 'Double Insurance' of Policy Immunity and Innovation Drive
Against the backdrop of high valuations in the overall US stock market and increased volatility among tech giants, the relative advantages of the healthcare sector are increasingly prominent. On one hand, medical demand is rigid and less affected by macroeconomic cycles; on the other hand, innovative therapies such as GLP-1 and oral weight-loss drugs are opening a long-term golden development cycle, providing continuous earnings growth for the sector. Today's Lilly event drove XLV up 1.2% and also led funds to refocus on the oral weight-loss layouts of Lilly's competitors Pfizer and Amgen.
Amgen's investigational oral GIP/GLP-1 bispecific molecule AMG-133 is already in Phase II, with early data also encouraging; Pfizer has introduced two oral PDE4B inhibitors through external partnerships. Given the huge market demand for oral weight-loss drugs, these companies are expected to see a valuation re-rating window in 2026-2027.
"We are on the eve of a paradigm shift in weight management," said a UBS healthcare strategy analyst. "Not only is the global obese population huge, oral drugs will expand weight-loss indications to broader populations such as overweight with prediabetes. Lilly's success will continue to catalyze the entire sector over the next five quarters." The analyst suggested investors adopt a "barbell" allocation strategy within the healthcare sector, combining leaders and innovative, high-elasticity targets.
Risk Warning and Next Steps
Despite the impressive Phase III data for Orforglipron, the FDA will still strictly review long-term safety indicators such as gastrointestinal tolerability and hepatobiliary toxicity that may be associated with oral GLP-1 drugs. In addition, Novo Nordisk's next-generation oral weight-loss drugs (such as oral Amycretin) are also advancing rapidly, and differentiated clinical evidence will be the key to the next stage of competition. Lilly will hold an investor conference call on August 8, during which the company will update capacity construction and pricing strategy. Investors should closely monitor management's guidance on launch and scaling.
Overall, Lilly's clinical victory is not only a major positive for its stock but also a microcosm of the US healthcare sector continuing to benefit from the innovation wave. As global weight-loss demand is further activated, pharmaceutical giants with platform-based R&D capabilities and scale production advantages are expected to continue serving as a core engine in the next phase of the US bull market. In a market environment where tech stocks are crowded in the short term, the healthcare sector is becoming an increasingly popular new allocation direction for institutional funds.
